AstraZeneca Stock Falls
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial, the drugmaker said Monday.
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,
AstraZeneca: TROPION-Breast01 Phase III Trial Fails To Achieve Statistical Significance
Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an upcoming medical conference and shared with regulatory authorities currently assessing applications for this specific indication.
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
Business Insider11h
AstraZeneca’s Market Position and Drug Pipeline Sustain Buy Rating Despite TB01 Trial Results
James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the ...
cnbctv181h
AstraZeneca Pharma gets nod to launch cancer drug durvalumab in India
The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...
STAT7d
News from ESMO: An AstraZeneca win in bladder cancer, and more
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...
Zawya10h
AstraZeneca to pump $50mln into new investments in Egypt
Arab Finance: AstraZeneca Egypt is planning to inject $50 million into new investments in Egypt, equivalent to nearly 50% of the company’s capital, the firm’s Country President Hatem Werdany stated.
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...